On September 8, 2026, Inhibrx Biosciences announced primary endpoint results from the Phase 2 portion of its HexAgon study evaluating INBRX-106 plus pembrolizumab versus pembrolizumab monotherapy in first-line HNSCC. The combination arm achieved a confirmed objective response rate (cORR) of 48.3% compared to 26.5% for the control, with median progression-free survival (PFS) of 9.6 months versus 4.9 months. Efficacy was particularly pronounced in HPV-positive patients, who demonstrated an 80.0% cORR and a 90.0% six-month PFS rate compared to 33.3% and 33.0%, respectively. Inhibrx plans to expand the trial by approximately 50 additional HPV+ patients to support a potential accelerated regulatory pathway, followed by a Phase 3 confirmatory study. The company is also advancing INBRX-106 in perioperative non-small cell lung cancer with results expected mid-2027. Inhibrx Biosciences operates as a clinical-stage biopharmaceutical company developing novel biologic therapeutic candidates.

Inhibrx Biosciences, Inc. entered into a second amendment to its loan and security agreement with Oxford Finance LLC, expanding the total credit facility to $500.0 million. The amendment includes a $325.0 million additional tranche consisting of a $100.0 million Term C Loan, which was immediately funded, and a potential $225.0 million Term D Loan. As part of the Term C funding, the company issued warrants to purchase 21,457 shares of common stock at an exercise price of $93.21 per share. Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates.

On June 15, 2026, the FDA accepted the Biologics License Application (BLA) for ozekibart (INBRX-109) for treating unresectable or metastatic conventional chondrosarcoma. The FDA reported no filing review issues and set a PDUFA goal date of April 14, 2027. Inhibrx Biosciences is a biotechnology company that develops therapeutic proteins.